Organs-on-chips at the frontiers of drug discovery

Nature Reviews Drug Discovery

Volumn 14, Issue 4, 2015, Pages 248-260

  Esch, Eric W ^a   Bahinski, Anthony ^b   Huh, Dongeun ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETICONE;

AUTOMATION; BIOLOGICAL FUNCTIONS; BIOMIMETICS; DRUG EFFICACY; DRUG SCREENING; HUMAN; INTERMETHOD COMPARISON; LAB ON A CHIP; MICROELECTROMECHANICAL SYSTEM; MICROFLUIDICS; MICROTECHNOLOGY; NANOMEDICINE; ORGAN ON CHIP; PERSONALIZED MEDICINE; PHARMACOLOGICAL PROCEDURES; PHENOTYPE; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; REVIEW; TOXICITY TESTING; ANIMAL; BIOLOGICAL MODEL; COMPUTER SIMULATION; DRUG DEVELOPMENT; DRUG INDUSTRY; HIGH THROUGHPUT SCREENING; PHARMACOKINETICS; PROCEDURES; RARE DISEASE; TRENDS;

ANIMALS; COMPUTER SIMULATION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MODELS, BIOLOGICAL; PHARMACOKINETICS; RARE DISEASES;

EID: 84926408953     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd4539     Document Type: Review

References (106)

1. Scannell J. W., Blanckley A., Boldon H. & Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nature Rev. Drug Discov. 11, 191-200 (2012
2. Paul S. M., et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nature Rev. Drug Discov. 9, 203-214 (2010
3. Caponigro G. & Sellers W. R. Advances in the preclinical testing of cancer therapeutic hypotheses. Nature Rev. Drug Discov. 10, 179-187 (2011
4. Kola I. & Landis J. Can the pharmaceutical industry reduce attrition rates?. Nature Rev. Drug Discov. 3, 711-715 (2004
5. Bowes J., et al. Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. Nature Rev. Drug Discov. 11, 909-922 (2012
6. Muller P. Y. & Milton M. N. The determination and interpretation of the therapeutic index in drug development. Nature Rev. Drug Discov. 11, 751-761 (2012
7. Folch A. & Toner M. Microengineering of cellular interactions. Annu. Rev. Biomed. Eng. 2, 227-256 (2000
8. Whitesides G. M., Ostuni E., Takayama S., Jiang X. Y. & Ingber D. E. Soft lithography in biology and biochemistry. Annu. Rev. Biomed. Eng. 3, 335-373 (2001
9. Beebe D. J., Mensing G. A. & Walker G. M. Physics and applications of microfluidics in biology. Annu. Rev. Biomed. Eng. 4, 261-286 (2002
10. Shamir E. R. & Ewald A. J. Three-dimensional organotypic culture: experimental models of mammalian biology and disease. Nature Rev. Mol. Cell Biol. 15, 647-664 (2014
11. Huh D., Hamilton G. A. & Ingber D. E. From 3D cell culture to organs-on chips. Trends Cell Biol. 21, 745-754 (2011
12. Yum K., Hong S. G., Healy K. E. & Lee L. P. Physiologically relevant organs on chips. Biotechnol. J. 9, 16-27 (2014
13. Huh D., et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668 (2010
14. Inamdar N. K. & Borenstein J. T. Microfluidic cell culture models for tissue engineering. Curr. Opin. Biotechnol. 22, 681-689 (2011
15. Huh D., et al. A human disease model of drug toxicity-induced pulmonary edema in a lung on a chip microdevice. Sci. Transl. Med. 4, 159ra147 (2012
16. Khetani S. R. & Bhatia S. N. Microscale culture of human liver cells for drug development. Nature Biotech. 26, 120-126 (2007
17. Bhatia S. N., Balis U. J., Yarmush M. L. & Toner M. Effect of cell-cell interactions in preservation of cellular phenotype: cocultivation of hepatocytes and nonparenchymal cells. FASEB J. 13, 1883-1900 (1999
18. Huh D., Torisawa Y. S., Hamilton G. A., Kim H. J. & Ingber D. E. Microengineered physiological biomimicry: organs-on chips. Lab Chip 12, 2156-2164 (2012
19. Ghaemmaghami A. M., Hancock M. J., Harrington H., Kaji H. & Khademhosseini A. Biomimetic tissues on a chip for drug discovery. Drug Discov. Today 17, 173-181 (2012
20. van Der Meer A. D. & van Den Berg A. Organs-on chips: breaking the in vitro impasse. Integr. Biol. (Camb.) 4, 461-470 (2012
21. Griffith L. G. & Swartz M. A. Capturing complex 3D tissue physiology in vitro. Nature Rev. Mol. Cell Biol. 7, 211-224 (2006
22. El Ali J., Sorger P. K. & Jensen K. F. Cells on chips. Nature 442, 403-411 (2006
23. Whitesides G. M. The origins and the future of microfluidics. Nature 442, 368-373 (2006
24. Sackmann E. K., Fulton A. L. & Beebe D. J. The present and future role of microfluidics in biomedical research. Nature 507, 181-189 (2014
25. Bhatia S. N. & Ingber D. E. Microfluidic organs-on chips. Nature Biotech. 32, 760-772 (2014
26. Olson H., et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul. Toxicol. Pharm. 32, 56-67 (2000
27. Mak I. W., Evaniew N. & Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am. J. Transl. Res. 6, 114-118 (2014
28. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507-3512 (2013
29. Henderson V. C., Kimmelman J., Fergusson D., Grimshaw J. M. & Hackam D. G. Threats to validity in the design and conduct of preclinical efficacy studies: a systematic review of guidelines for in vivo animal experiments. PLoS Med. 10, e1001489 (2013
30. Li F., Yin Z., Jin G., Zhao H. & Wong S. T. Chapter 17: bioimage informatics for systems pharmacology. PLoS Comput. Biol. 9, e1003043 (2013
31. Polini A., et al. Organs-on a chip: a new tool for drug discovery. Expert Opin. Drug Dis. 9, 335-352 (2014
32. Song J. W., et al. Microfluidic endothelium for studying the intravascular adhesion of metastatic breast cancer cells. PLoS ONE 4, e5756 (2009
33. Bersini S., et al. A microfluidic 3D in vitro model for specificity of breast cancer metastasis to bone. Biomaterials 35, 2454-2461 (2014
34. Businaro L., et al. Cross talk between cancer and immune cells: exploring complex dynamics in a microfluidic environment. Lab Chip 13, 229-239 (2013
35. Kunze A., et al. Astrocyte-neuron co culture on microchips based on the model of SOD mutation to mimic ALS. Integr. Biol. (Camb.) 5, 964-975 (2013
36. Wang G., et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart on chip technologies. Nature Med. 20, 616-623 (2014
37. Aref A. R., et al. Screening therapeutic EMT blocking agents in a three-dimensional microenvironment. Integr. Biol. (Camb.) 5, 381-389 (2013
38. Vidi P. A., et al. Disease-on a chip: mimicry of tumor growth in mammary ducts. Lab Chip 14, 172-177 (2014
39. Tatosian D. A. & Shuler M. L. A novel system for evaluation of drug mixtures for potential efficacy in treating multidrug resistant cancers. Biotechnol. Bioeng. 103, 187-198 (2009
40. Torisawa Y. S., et al. Bone marrow-on a chip replicates hematopoietic niche physiology in vitro. Nature Methods 11, 663-669 (2014
41. Berdichevsky Y., Staley K. J. & Yarmush M. L. Building and manipulating neural pathways with microfluidics. Lab Chip 10, 999-1004 (2010
42. Snouber L. C., et al. Metabolomics-on a chip of hepatotoxicity induced by anticancer drug flutamide and its active metabolite hydroxyflutamide using HepG2/C3a microfluidic biochips. Toxicol. Sci. 132, 8-20 (2013
43. Mao S., Gao D., Liu W., Wei H. & Lin J. M. Imitation of drug metabolism in human liver and cytotoxicity assay using a microfluidic device coupled to mass spectrometric detection. Lab Chip 12, 219-226 (2012
44. Choucha-Snouber L., et al. Investigation of ifosfamide nephrotoxicity induced in a liver-kidney co culture biochip. Biotechnol. Bioeng. 110, 597-608 (2013
45. Agarwal A., Goss J. A., Cho A., McCain M. L. & Parker K. K. Microfluidic heart on a chip for higher throughput pharmacological studies. Lab Chip 13, 3599-3608 (2013
46. Grosberg A., Alford P. W., McCain M. L. & Parker K. K. Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. Lab Chip 11, 4165-4173 (2011
47. McCain M. L., Sheehy S. P., Grosberg A., Goss J. A. & Parker K. K. Recapitulating maladaptive multiscale remodeling of failing myocardium on a chip. Proc. Natl Acad. Sci. USA 110, 9770-9775 (2013
48. Thavandiran N., et al. Design and formulation of functional pluripotent stem cell-derived cardiac microtissues. Proc. Natl Acad. Sci. USA 110, E4698-E4707 (2013
49. Capulli A. K., et al. Approaching the in vitro clinical trial: engineering organs on chips. Lab Chip 14, 3181-3186 (2014
50. Thorneloe K. S., et al. An orally active TRPV4 channel blocker prevents and resolves pulmonary edema induced by heart failure. Sci. Transl. Med. 4, 159ra148 (2012
51. Kramer J. A., Sagartz J. E. & Morris D. L. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nature Rev. Drug Discov. 6, 636-649 (2007
52. LeCluyse E. L., Witek R. P., Andersen M. E. & Powers M. J. Organotypic liver culture models: meeting current challenges in toxicity testing. Crit. Rev. Toxicol. 42, 501-548 (2012
53. Baudoin R., et al. Evaluation of seven drug metabolisms and clearances by cryopreserved human primary hepatocytes cultivated in microfluidic biochips. Xenobiotica 43, 140-152 (2013
54. Chao P., Maguire T., Novik E., Cheng K. C. & Yarmush M. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem. Pharmacol. 78, 625-632 (2009
55. Kim H. J., Huh D., Hamilton G. & Ingber D. E. Human gut on a chip inhabited by microbial flora that experiences intestinal peristalsis-like motions and flow. Lab Chip 12, 2165-2174 (2012
56. Kim H. J. & Ingber D. E. Gut on a chip microenvironment induces human intestinal cells to undergo villus differentiation. Integr. Biol. (Camb.) 5, 1130-1140 (2013
57. Gao D., Liu H., Lin J. M., Wang Y. & Jiang Y. Characterization of drug permeability in Caco 2 monolayers by mass spectrometry on a membrane-based microfluidic device. Lab Chip 13, 978-985 (2013
58. Lee J. B. & Sung J. H. Organ on a chip technology and microfluidic whole-body models for pharmacokinetic drug toxicity screening. Biotechnol. J. 8, 1258-1266 (2013
59. Sung J. H., et al. Microfabricated mammalian organ systems and their integration into models of whole animals and humans. Lab Chip 13, 1201-1212 (2013
60. Imura Y., Sato K. & Yoshimura E. Micro total bioassay system for ingested substances: assessment of intestinal absorption hepatic metabolism and bioactivity. Anal. Chem. 82, 9983-9988 (2010
61. Imura Y., Yoshimura E. & Sato K. Micro total bioassay system for oral drugs: evaluation of gastrointestinal degradation intestinal absorption hepatic metabolism and bioactivity. Anal. Sci. 28, 197-199 (2012
62. Imura Y., Yoshimura E. & Sato K. Microcirculation system with a dialysis part for bioassays evaluating anticancer activity and retention. Anal. Chem. 85, 1683-1688 (2013
63. Wikswo J. P., et al. Scaling and systems biology for integrating multiple organs-on a chip. Lab Chip 13, 3496-3511 (2013
64. Sung J. H. & Shuler M. L. A micro cell culture analog (μCCA) with 3D hydrogel culture of multiple cell lines to assess metabolism-dependent cytotoxicity of anti-cancer drugs. Lab Chip 9, 1385-1394 (2009
65. Sung J. H., Kam C. & Shuler M. L. A microfluidic device for a pharmacokinetic-pharmacodynamic (PK-PD) model on a chip. Lab Chip 10, 446-455 (2010
66. Zheng W., Thorne N. & McKew J. C. Phenotypic screens as a renewed approach for drug discovery. Drug Discov. Today 18, 1067-1073 (2013
67. Lee J. A., Uhlik M. T., Moxham C. M., Tomandl D. & Sall D. J. Modern phenotypic drug discovery is a viable neoclassic pharma strategy. J. Med. Chem. 55, 4527-4538 (2012
68. Trietsch S. J., Israels G. D., Joore J., Hankemeier T. & Vulto P. Microfluidic titer plate for stratified 3D cell culture. Lab Chip 13, 3548-3554 (2013
69. Demonaco H. J., Ali A. & Hippel E. The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy 26, 323-332 (2006
70. Swinney D. C. & Anthony J. How were new medicines discovered?. Nature Rev. Drug Discov. 10, 507-519 (2011
71. Kalchman J., et al. A three-dimensional microfluidic tumor cell migration assay to screen the effect of anti-migratory drugs and interstitial flow. Microfluid. Nanofluid. 14, 969-981 (2013
72. Melnikova I. Rare diseases and orphan drugs. Nature Rev. Drug Discov. 11, 267-268 (2012
73. van Der Meer A. D., Orlova V. V., ten Dijke P., van Den Berg A. & Mummery C. L. Three-dimensional co cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. Lab Chip 13, 3562-3568 (2013
74. Phan V. H., et al. An update on ethnic differences in drug metabolism and toxicity from anti-cancer drugs. Expert Opin. Drug Metab. Toxicol. 7, 1395-1410 (2011
75. US Food and Drug Administration Center for Drug Evaluation and Research Center for Biologics Evaluation and Research & Center for Devices and Radiological Health. Guidance for Industry: Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products (US FDA 2012
76. Ma L., et al. Towards personalized medicine with a three-dimensional micro-scale perfusion-based two-chamber tissue model system. Biomaterials 33, 4353-4361 (2012
77. Polimanti R., Piacentini S., Manfellotto D. & Fuciarelli M. Human genetic variation of CYP450 superfamily: analysis of functional diversity in worldwide populations. Pharmacogenomics 13, 1951-1960 (2012
78. Chen Z., et al. A murine lung cancer co clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012
79. Torchilin V. P. Multifunctional nanocarriers. Adv. Drug Deliv. Rev. 58, 1532-1555 (2006
80. Boisselier E. & Astruc D. Gold nanoparticles in nanomedicine: preparations imaging diagnostics therapies and toxicity. Chem. Soc. Rev. 38, 1759-1782 (2009
81. Kim Y., et al. Probing nanoparticle translocation across the permeable endothelium in experimental atherosclerosis. Proc. Natl Acad. Sci. USA 111, 1078-1083 (2014
82. Prabhakarpandian B., et al. SyM-BBB: a microfluidic blood brain barrier model. Lab Chip 13,1093-1101 (2013
83. Griep L. M., et al. BBB on chip: microfluidic platform to mechanically and biochemically modulate blood-brain barrier function. Biomed. Microdevices 15, 145-150 (2013
84. Achyuta A. K. H., et al. A modular approach to create a neurovascular unit on a chip. Lab Chip 13, 542-553 (2013
85. Booth R. & Kim H. Characterization of a microfluidic in vitro model of the blood-brain barrier (mu BBB). Lab Chip 12, 1784-1792 (2012
86. Nelson C. E., et al. Balancing cationic and hydrophobic content of PEGylated siRNA polyplexes enhances endosome escape stability blood circulation time and bioactivity in vivo. ACS Nano 7, 8870-8880 (2013
87. Flaim C. J., Chien S. & Bhatia S. N. An extracellular matrix microarray for probing cellular differentiation. Nature Methods 2, 119-125 (2005
88. Berthier E., Young E. W. & Beebe D. Engineers are from PDMS-land biologists are from polystyrenia. Lab Chip 12, 1224-1237 (2012
89. Wong I. & Ho C. M. Surface molecular property modifications for poly (dimethylsiloxane) (PDMS) based microfluidic devices. Microfluid. Nanofluid. 7, 291-306 (2009
90. Domansky K., et al. Clear castable polyurethane elastomer for fabrication of microfluidic devices. Lab Chip 13, 3956-3964 (2013
91. van Midwoud P. M., Janse A., Merema M. T., Groothuis G. M. & Verpoorte E. Comparison of biocompatibility and adsorption properties of different plastics for advanced microfluidic cell and tissue culture models. Anal. Chem. 84, 3938-3944 (2012
92. Ghafar-Zadeh E., Waldeisen J. R. & Lee L. P. Engineered approaches to the stem cell microenvironment for cardiac tissue regeneration. Lab Chip 11, 3031-3048 (2011
93. Mathur A., et al. Human induced pluripotent stem cell-based microphysiological tissue models of myocardium and liver for drug development. Stem Cell Res. Ther. 4 (Suppl. 1), S14 (2013
94. Neuzil P., Giselbrecht S., Lange K., Huang T. J. & Manz A. Revisiting lab on a chip technology for drug discovery. Nature Rev. Drug Discov. 11, 620-632 (2012
95. Messner S., Agarkova I., Moritz W. & Kelm J. Multi-cell type human liver microtissues for hepatotoxicity testing. Arch. Toxicol. 87, 209-213 (2013
96. DesRochers T. M., Suter L., Roth A. & Kaplan D. L. Bioengineered 3D human kidney tissue a platform for the determination of nephrotoxicity. PLoS ONE 8, e59219 (2013
97. Meyvantsson I., Warrick J. W., Hayes S., Skoien A. & Beebe D. J. Automated cell culture in high density tubeless microfluidic device arrays. Lab Chip 8, 717-724 (2008
98. Bouhifd M., et al. Mapping the human toxome by systems toxicology. Basic Clin. Pharmacol. Toxicol. 115, 24-31 (2014
99. US Food and Drug Administration Center for Drug Evaluation and Research & Center for Biologics Evaluation and Research. Guidance for Industry: Product Development Under the Animal Rule (US FDA 2014
100. Esch M., King T. & Shuler M. The role of body on a chip devices in drug and toxicity studies. Annu. Rev. Biomed. Eng. 13, 55-72 (2011
101. Williamson A., Singh S., Fernekorn U. & Schober A. The future of the patient-specific body on a chip. Lab Chip 13, 3471-3480 (2013
102. Sutherland M. L., Fabre K. M. & Tagle D. A. The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Res. Ther. 4 (Suppl. 1), I1 (2013
103. Dambach D. M. & Uppal H. Improving risk assessment. Sci. Transl. Med. 4, 159ps22 (2012
104. Jeon J. S., et al. Generation of 3D functional microvascular networks with human mesenchymal stem cells in microfluidic systems. Integr. Biol. (Camb.) 6, 555-563 (2014
105. Lee H., Kim S., Chung M., Kim J. H. & Jeon N. L. A bioengineered array of 3D microvessels for vascular permeability assay. Microvasc. Res. 91, 90-98 (2014
106. Fischbach C., et al. Engineering tumors with 3D scaffolds. Nature Methods 4, 855-860 (2007